101 related articles for article (PubMed ID: 21799030)
21. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
22. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
Corti A; Gasparri AM; Sacchi A; Colombo B; Monieri M; Rrapaj E; Ferreri AJM; Curnis F
Mol Pharm; 2020 Oct; 17(10):3813-3824. PubMed ID: 32805112
[TBL] [Abstract][Full Text] [Related]
23. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
[TBL] [Abstract][Full Text] [Related]
24. Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells.
Seynhaeve AL; Vermeulen CE; Eggermont AM; ten Hagen TL
Cell Biochem Biophys; 2006; 44(1):157-69. PubMed ID: 16456244
[TBL] [Abstract][Full Text] [Related]
25. Chromogranin A regulates tumor self-seeding and dissemination.
Dondossola E; Crippa L; Colombo B; Ferrero E; Corti A
Cancer Res; 2012 Jan; 72(2):449-59. PubMed ID: 22139379
[TBL] [Abstract][Full Text] [Related]
26. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
[TBL] [Abstract][Full Text] [Related]
27. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study.
Gutman M; Sofer D; Lev-Chelouche D; Merimsky O; Klausner JM
Invasion Metastasis; 1997; 17(4):169-75. PubMed ID: 9778589
[TBL] [Abstract][Full Text] [Related]
28. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas.
van Laarhoven HW; Gambarota G; Heerschap A; Lok J; Verhagen I; Corti A; Toma S; Gallo Stampino C; van der Kogel A; Punt CJ
Invest New Drugs; 2006 Jan; 24(1):27-36. PubMed ID: 16379040
[TBL] [Abstract][Full Text] [Related]
29. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides.
Zarovni N; Monaco L; Corti A
Hum Gene Ther; 2004 Apr; 15(4):373-82. PubMed ID: 15053862
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases.
Rossi CR; Pasquali S; Mocellin S; Vecchiato A; Campana LG; Pilati P; Zanon A; Nitti D
Ann Surg Oncol; 2010 Nov; 17(11):3000-7. PubMed ID: 20429035
[TBL] [Abstract][Full Text] [Related]
33. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V; Santoro A; Bennicelli E; Punt CJ; Citterio G; Timmer-Bonte JN; Caligaris Cappio F; Lambiase A; Bordignon C; van Herpen CM
Br J Cancer; 2009 Jul; 101(2):219-24. PubMed ID: 19568235
[TBL] [Abstract][Full Text] [Related]
34. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
J Infus Chemother; 1995; 5(2):73-81. PubMed ID: 8521239
[TBL] [Abstract][Full Text] [Related]
35. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
[TBL] [Abstract][Full Text] [Related]
36. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.
Brunstein F; Hoving S; Seynhaeve AL; van Tiel ST; Guetens G; de Bruijn EA; Eggermont AM; ten Hagen TL
J Natl Cancer Inst; 2004 Nov; 96(21):1603-10. PubMed ID: 15523089
[TBL] [Abstract][Full Text] [Related]
37. Regulation of tumor growth by circulating full-length chromogranin A.
Curnis F; Dallatomasina A; Bianco M; Gasparri A; Sacchi A; Colombo B; Fiocchi M; Perani L; Venturini M; Tacchetti C; Sen S; Borges R; Dondossola E; Esposito A; Mahata SK; Corti A
Oncotarget; 2016 Nov; 7(45):72716-72732. PubMed ID: 27683038
[TBL] [Abstract][Full Text] [Related]
38. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Lyu MA; Kurzrock R; Rosenblum MG
Biochem Pharmacol; 2008 Feb; 75(4):836-46. PubMed ID: 18082672
[TBL] [Abstract][Full Text] [Related]
39. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII).
Wu PC; Alexander HR; Huang J; Hwu P; Gnant M; Berger AC; Turner E; Wilson O; Libutti SK
Cancer Res; 1999 Jan; 59(1):205-12. PubMed ID: 9892208
[TBL] [Abstract][Full Text] [Related]
40. Regulatory peptides from chromogranin A and secretogranin II: putative modulators of cells and tissues involved in inflammatory conditions.
Helle KB
Regul Pept; 2010 Nov; 165(1):45-51. PubMed ID: 19800929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
